Human CDC2-like kinase 1 (CLK1): A novel target for Alzheimer's disease

Current Drug Targets

Volumn 15, Issue 5, 2014, Pages 539-550

  Jain, Princi ^a   Karthikeyan, Chandrabose ^a   Moorthy, N S Hari Narayana ^a,b   Waiker, Digambar Kumar ^a   Jain, Arvind Kumar ^a   Trivedi, Piyush ^a  

^a UNIVERSITY INSTITUTE OF TECHNOLOGY   (India)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Alzheimer's disease; Cdc2 like kinase (CLK); CLK1 inhibitors; Protein kinases; SR proteins

Indexed keywords

AKN 028; ALKALOID; BIOLOGICAL FACTOR; CDC2 LIKE KINASE; CDC2 LIKE KINASE 1; CDC2 LIKE KINASE 2; CDC2 LIKE KINASE 3; CDC2 LIKE KINASE 4; CLIOQUINOL; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 7; DEBROMOHYMENIALDISINE; DICHLOROINDOLYL ENAMINONITRILE; FLAVONOID; HYMENIALDISINE; INDOLOCARBAZOLE; LEUCETTAMINE B; LEUCETTINE L41; MERIDIANIN; MRNA SPLICING FACTOR 45; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; QUINOLINE DERIVATIVE; RIBONUCLEOPROTEIN; SERINE ARGININE RICH PROTEIN; TAU PROTEIN; UBIQUINONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARIOLIN; VARIOLIN B;

ALZHEIMER DISEASE; ARTICLE; DRUG RESEARCH; DRUG TARGETING; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN FUNCTION; PROTEIN STRUCTURE; RNA SPLICING;

ALZHEIMER DISEASE; ANIMALS; DRUG DISCOVERY; HUMANS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; TAU PROTEINS;

EID: 84898607348     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450115666140226112321     Document Type: Article

References (84)

1. Menegay HJ, Myers MP, Moeslein FM, Landreth GE. Biochemical characterization and localization of the dual specificity kinase CLK1. J Cell Sci 2000; 113: 3241-3253.
2. Hanks SK, Quinn AM. Protein kinase catalytic domain sequence database: identification of conserved features of primary structure and classification of family members. Meth Enzymol 1991; 200: 38-62.
3. Hanks SK, Quinn AM, Hunter T. The protein kinase family: Conserved features and deduced phylogeny of the catalytic domains. Science 1988; 241: 42-52.
4. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990; 61: 203-212.
5. Myers MP, Murphy MB, Landreth K. The dual-specificity CLK kinase induces neuronal differentiation of PC12 cells. Mol Cell Biol 1994; 14(10): 6954-6961.
6. Ballou L, Luther H, Thomas G. MAP2 kinase and 70K S6 kinase lie on distinct signalling pathways. Nature 1991; 349: 348-350.
7. Jiang K, Patel NA, Watson JE, et al. Akt2 regulation of Cdc2-like kinases (Clk/Sty), serine/arginine-rich (SR) protein phosphorylation, and insulin-induced alternative splicing of PKCpII messenger ribonucleic acid. Endocrinol 2009; 150(5): 2087-2097.
8. Lee K, Du C, Horn M, Rabinow L. Activity and autophosphorylation of LAMMER protein kinases. J Biol Chem 1996; 271: 27299-27303.
9. Rosenthal AS, Tanega C, Shen M, et al. Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk). Bioorg Med Chem Lett 2011; 21: 3152-3158.
10. Mott BT, Tanega C, Shen M, et al. Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk). Bioorg Med Chem Lett 2009; 19; 6700-6705.
11. Hagiwara M. Alternative splicing: A new drug target of the post-genome era. Biochim Biophy Acta 2005; 1754: 324-331.
12. Bullock AN, Das S, Debreczeni JE, et al. Kinase domain insertions define distinct roles of CLK kinases in SR protein phosphorylation. Structure 2009; 17: 352-362.
13. Howell B, Afar D, Lew J, et al. STY, a tyrosine phosphorylating enzyme with sequence homology to serine/threonine kinases. Mol Cell Biol 1991; 11: 568-572.
14. Ngo JCK, Chakrabarti S, Ding JH, et al. Interplay between SRPK and Clk/Sty kinases in phosphorylation of the splicing factor ASF/SF2 is regulated by a docking motif in ASF/SF2. Mol Cell 2005; 20: 77-89.
15. Moeslein FM, Myers MP, Landreth GE. The CLK family kinases, CLK1 and CLK2, phosphorylate and activate the tyrosine phospha-tase, PTP-1B. J Biol Chem 1999; 274(38): 26697-26704.
16. Yun B, Farkas R, Lee K, Rabinow L. The Doa locus encodes a member of a new protein kinase family and is essential for eye and embryonic development in Drosophila melanogaster. Genes Dev 1994; 8: 1160-1173.
17. Colwill K, Fengi LL, Yeakleyi JM, et al. SRPK1 and Clk/Sty protein kinases show distinct substrate specificities for serine/arginine-rich splicing factors. J Biol Chem 1996; 271(40): 24569-24575.
18. Colwill K, Pawson T, Andrews B, et al. The Clk/Sty protein kinase phosphorylates SR splicing factors and regulates their intranuclear distribution. EMBO J 1996; 15: 265-275.
19. Duncan PI, Stojdl DF, Marius RM, Bell JC. In vivo regulation of alternative pre-mRNA splicing by the Clk1 protein kinase. Mol Cell Biol 1997; 17: 5996-6001.
20. Lee KY, Qi Z, Yu YP, Wangji JY. Neuronal Cdc24ike kinases: Neuron-specific Forms of Cdk5. Int J Biochem Cell Bid 1997; 29(7): 951-958.
21. Lew J, Beaudette K, Litwin CME, Wang JH. Purification and characterization of a novel proline-directed protein kinase from bovine brain. J Biol Chem 1992; 267: 13383-13390.
22. Lew J, Huang QQ, Qi Z, et al. A brain-specific activator of cyclin-dependent kinase 5. Nature 1994; 371: 423-426.
23. Lew J, Qi Z, Huang QQ, et al. Structure, function, and regulation of neuronal Cdc2-like protein kinase. Neurobiol Aging 1995; 16(3): 263-270.
24. Lee KY, Clark AW, Rosales JL, Chapman K, Fung T, Johnston RN. Elevated neuronal Cdc2-like kinase activity in the Alzheimer disease brain. Neurosci Res 1999; 34: 21-29.
25. Johnson K, Smith K. Molecular cloning of a novel human cdc2/CDC28-like protein kinase. J Biol Chem 1991; 266: 3402-3407.
26. Aubol BE, Plocinik RM, Hagopian JC, et al. Partitioning RS domain phosphorylation in an SR protein through the CLK and SRPK protein kinases. J Mol Biol 2013; 425: 2894-2909.
27. Velazquez-Dones A, Hagopian JC, Ma CT, et al. Mass spectromet-ric and kinetic analysis of ASF/SF2 phosphorylation by SRPK1 and Clk/Sty. J Biol Chem 2005; 280: 41761-41768.
28. Ngo JC, Giang K, Chakrabarti S, et al. A sliding docking interaction is essential for sequential and processive phosphorylation of an SR protein by SRPK1. Mol Cell 2008; 9: 563-576.
29. Wong R, Balachandran A, Mao AYQ, Dobson W, Gray-Owen S, Cochrane A. Differential effect of CLK SR kinases on HIV-1 gene expression: potential novel targets for therapy. Retrovirol 2011; 8: 47-59.
30. Yomoda J, Muraki M, Kataoka N, et al. Combination of Clk family kinase and SRp75 modulates alternative splicing of Adenovirus E1A. Genes to Cells 2008; 13: 233-244.
31. Liu Y, Conaway L, Bethard JR, et al. Phosphorylation of the alternative mRNA SPF45 by Clk1 regulates its splice site utilization, cell migration and invasion. Nucleic Acids Res 2013; 41(9): 4949-4962.
32. Sampath J, Long PR, Shepard RL, et al. Human SPF45, a splicing factor, has limited expression in normal tissues, is overexpressed in many tumors, and can confer a multidrug-resistant phenotype to cells. Am J Pathol 2003; 163: 1781-1790.
33. Perry WL 3rd, Shepard RL, Sampath J, et al. Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to antican-cer drugs when overexpressed-a phenotype partially reversed by selective estrogen receptor modulators. Cancer Res 2005; 65: 6593-6600.
34. Kelley LC, Hayes KE, Ammer AG, Martin KH, Weed SA. Cortac-tin phosphorylated by ERK1/2 localizes to sites of dynamic actin regulation and is required for carcinoma lamellipodia persistence. PLoS One 2010; 5: 13847.
35. Illenberger S, Zheng-Fischerhofer Q, Preuss U, et al. The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer's disease. Mol Biol Cell 1998; 9: 1495-1512.
36. Iqbal K, Grundke-Iqbal I. Alzheimer abnormally phosphorylated tau is more hyperphosphorylated than the fetal tau and causes the disruption of microtubules. Neurobiol Aging 1995; 16: 375-379.
37. Stanford PM, Halliday GM, Brooks WS, et al. Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: Expansion of the disease phenotype caused by tau gene mutations. Brain 2000; 123: 880-893.
38. Liu F, Gong CX. Tau exon 10 alternative splicing and tauopathies. Mol Neurodegeneration 2008; 3: 8(1-10).
39. Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neu-rosci 2007; 8: 663-672.
40. Mayeda A, Helfman DM, Krainer AR. Modulation of exon skipping and inclusion by heterogeneous nuclear ribonucleoprotein A1 and pre-mRNA splicing factor SF2/ASF [published erratum appears in Mol Cell Biol 1993; 13(7): 4458]. Mol Cell Biol 1993; 13: 2993-3001.
41. Mandelkow EM, Mandelkow E. Tau in Alzheimer's disease. Trends Cell Biol 1998; 8: 425-427.
42. Berson A, Barbash S, Shaltiel G, et al. Cholinergic-associated loss of hnRNP-A/B in Alzheimer's disease impairs cortical splicing and cognitive function in mice. EMBO Mol Med 2012; 4: 730-742.
43. Mayeda A, Krainer AR. Regulation of alternative pre-mRNA splicing by hnRNP A1 and splicing factor SF2. Cell 1992; 68: 365-375.
44. Chen M, Manley JL. Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Nat Rev Mol Cell Biol 2009; 10: 741-754
45. Manley JL, Tacke R. SR proteins and splicing control. Genes Dev 1996; 10: 1569-1579.
46. Troulinaki K, Bano D. Mitochondrial deficiency: a double-edgeds word for aging and neurodegeneration. Frontiers in Genetics 2012; 3: Article 244 (1-10).
47. Lakowski B, Hekimi S. Determination of life-span in Caenorhabdi-tis elegans by four clock genes. Science 1996; 272: 1010-1013.
48. Felkai S, Ewbank JJ, Lemieux J, Labbe JC, Brown GG, Hekimi S. CLK-1 controls respiration, behavior and aging in the nematode Caenorhabditis elegans. EMBO J 1999; 18: 1783-1792.
49. Cherny RA, Atwood CS, Xilinas ME, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta- amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001; 30: 665-676.
50. Kaur D, Yantiri F, Rajagopalan S, et al. Geneticor pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 2003; 37: 899-909.
51. Nguyen T, Hamby A, Massa SM. Clioquinol down-regulates mutant hunting in expression in vitro and mitigates pathology in a Huntington's disease mouse model. Proc Natl Acad Sci USA 2005; 102: 11840-11845.
52. Ma CT, Velazquez-Dones A, Hagopian JC, Ghosh G, Fu XD, Adams JA. Ordered multi-site phosphorylation of the splicing factor ASF/SF2 by SRPK1. J Mol Biol 2008; 376: 55-68.
53. Hekimi S, McBride K, Hihi AK, et al. Quinoline Derivatives. WO 2008/014602 A1, February 7, 2008.
54. Ayton S, Lei P, Bush AI. Metallostasis in Alzheimer's disease. Free Radical Biol Med 2013; 62: 76-89.
55. Wang Y, Branicky R, Stepanyan Z, et al. The anti-neurodegeneration drug clioquinol inhibits the aging-associated protein CLK-1. J Biol Chem 2009; 284: 314-323.
56. Du T, Filiz G, Caragounis A, Crouch PJ, White AR. Clioquinol promotes cancer cell toxicity through tumor necrosis factor a release from macrophages. J Pharmacol Exp Ther 2008; 324: 360-367.
57. Fedorov O, Huber K, Eisenreich A, et al. Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem Biol 2011; 18: 67-76.
58. Larsen LK, Moore RE, Patterson GM. Beta-Carbolines from the blue-green alga Dichothrix baueriana. J Nat Prod 1994; 57: 419-421.
59. Debdab M, Carreaux F, Renault S, et al. Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge Leucettamine B: Modulation of alternative pre-RNA splicing. J Med Chem 2011; 54: 4172-4186.
60. Gompel M, Leost M, De Kier Joffe EB, et al. Meridianins, a new family of protein kinase inhibitors isolated from the ascidian Aplid-ium meridianum. Bioorg Med Chem Lett 2004; 14: 1703-1707.
61. Giraud F, Alves G, Debiton E, et al. Synthesis, protein kinase inhibitory potencies, and in vitro antiproliferative activities of merid-ianin derivatives. J Med Chem 2011; 54: 4474-4489.
62. Trimurtulu G, Faulkner DJ, Perry NB, et al. Alkaloids from the antarctic sponge Kirkpatrickia varialosa. Part 2: Variolin A and N (3')-methyl tetrahydrovariolin. Tetrahedron 1994; 50: 3993-4000.
63. Perry NB, Ettouati L, Litaudon M, Blunt JW, Munro MHG. Alkaloids from the antarctic sponge Kirkpatrickia varialosa.: Part 1: Variolin b, a new antitumour and antiviral compound. Tetrahedron 1994; 50: 3987-3992.
64. Walker SR, Carter EJ, Huff BC, Morris JC. Variolins and related alkaloids. Chem Rev 2009; 109: 3080-3098.
65. Carter E. Unpublished results, PhD candidate, University of Adelaide, 2005-2011.
66. Huff BC. Unpublished results, PhD candidate, The development of pyrrolopyrimidines as kinase inhibitors. University of New South Wales, 2011.
67. Echalier A, Bettayeb K, Ferandin Y, et al. Meriolins, (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex. J Med Chem 2008; 51: 737-751.
68. Bettayeb K, Tirado OM, Marionneau-Lambot S, et al. Meriolins, a new class of cell death-inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases. Cancer Res 2007; 67: 8325-8334.
69. Jarry M, Schouft MT, Liger F, et al. Effects of a series of meriolins, new class of cyclin-dependent kinase inhibitors, on glioma proliferation, Glia 2009; 57: S168.
70. Nguyen TB, Lozach O, Surpateanu G, et al. Synthesis, biological evaluation, and molecular modeling of natural and unnatural fla-vonoidal alkaloids, inhibitors of kinases. J Med Chem 2012; 55: 2811-2819.
71. Smith B, Medda F, Gokhale V, Dunckley T, Hulme C. Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: A new avenue for a disease modifying treatment of Alzheimer's". ACS Chem. Neurosci. 2012; 3(11): 857-872.
72. Eriksson A, Hermanson M, Wickström M, et al. The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia. Blood Cancer J 2012; 2: e81.
73. Meijer L, Thunnissen AMWH, White AW, et al. Inhibition of cyclin-dependent kinases, GSK-3p and CK1 by hymenialdisine, a marine sponge constituent. Chem Biol 2000; 7: 51-63.
74. Saleem RSZ, Lansdell TA, Tepe JJ. Synthesis and evaluation of debromohymenialdisine-derived Chk2 inhibitors. Bioorg Med Chem 2012; 20: 1475-1481.
75. Perni RB, Bemis J, Nunes JJ, Szczepankiewicz BG. Inhibitors of the CDC2-like kinases and Methods of use thereof. WO 2009/085226 A2, July 9, 2009.
76. Hekimi S, McBride K, Hihi AK, et al. New Quinoline Derivatives. 60/832937, July 25, 2006.
77. Coombs TC, Tanega C, Shen M, et al. Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phos-phorylation-regulated (Dyrk) kinases: Development of chemical probe ML315. Bioorg Med Chem Lett 2013; 23(12): 3654-3661.
78. Coulibaly WK, Paquin L, Bénie A, et al. Synthesis of N,N0-bis(5-arylidene-4-oxo-3,5-dihydro-4H-imidazol-2-yl)diamines bearing various linkers and biological evaluation as potential inhibitors of kinases. Eur J Med Chem 2012; 58: 581-590.
79. Loidreau Y, Marchand P, Dubouilh-Benard C, et al. Synthesis and biological evaluation of N-arylbenzo[b]thieno[3,2-d]pyrimidin-4amines and their pyrido and pyrazino analogues as Ser/Thr kinase inhibitors. Eur J Med Chem 2012; 58: 171-183.
80. Loidreau Y, Marchand P, Dubouilh-Benard C, et al. Synthesis and biological evaluation of N-aryl-7-methoxybenzo[b]furo[3,2-d]pyrimidin-4-amines and their N-arylbenzo[b]thieno[3,2-d]pyrimidin-4-amine analogues as dual inhibitors of CLK1 and DYRK1A kinases. Eur J Med Chem 2013; 59: 283-295.
81. Deau E, Loidreau Y, Marchand P, et al. Synthesis of novel 7-substituted pyrido[2',3':4,5]furo[3,2-d]pyrimidin-4-amines and their N-aryl analogues and evaluation of their inhibitory activity against Ser/Thr kinases. Bioorg Med Chem Lett 2013; 23(24): 6784-6788.
82. Huber K, Brault L, Fedorov O, et al. 7,8-Dichloro-1-oxo-p-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes. J Med Chem 2012; 55(1): 403-413.
83. Brookmeyer R, Johnson E, Ziegler-Graham K, MH Arrighi. Forecasting the global burden of Alzheimer's disease. Alzheimer's and Dementia 2007; 3(3): 186-191.
84. http://www.alz.co.uk/research/WorldAlzheimerReport2013.pdf